Ras proto-oncogene encodes for small GTPases, downstream of epidermal growth factor receptor (EGFR)
in the RAS/RAF/MAPK pathway. Wild type KRAS is associated with EGFR-signalling activation. In
normal physiological conditions, it is activated by upstream signals when the GTP is exchanged with
GDP. Playing an important role in regulation of differentiation and cell growth, RasGTPases behave as
genetic switches. This transient process of GAP-mediated GTP hydrolysis becomes altered when the
Kras gene is mutated. The most common Kras mutations are found in codon 12 and 13 and 61. Some
other noncanonical mutations have been reported in codon 11, 14, 15, 17, 18, 19, 20, 22, 27, 30, 31,
117, 146 and 154. We aimed to demonstrate the conformational changes induced in two novel K RAS
variants, p.E31K and p.G138V, identified in two CRC patients, which may account for transformative
capacity by biochemical and signalling readouts in these patients. Dynamical implications and functional
impact of variants were determined by in silico analysis and molecular docking of variants with GTP.
MutationTaster was used for functional analysis of genetic variants and three-dimensional structure
of mutant proteins were built by Swiss-Model and were further subjected to structural alignment and
stability studies by I-Mutant Suite and DUET server. Both variants were predicted as ‘disease causing’
and protein stability analysis revealed p.G138V to be more destabilizing variant than p.E31K. When
three-dimensional structures of variants were subjected to molecular docking with GTP, the mutated
KRAS showed low binding affinity to the GTP as compared to the wild-type KRAS protein.